Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.TapImmune has received notice of allowance (NOA) entitled, 'Poxviridae Treatment' from the US Patent and Trademark Office (USPTO) for US patent application number 20100303894, in relation to a vaccine composition containing TAP-1 and/or TAP-2 to augment the antigen processing capability of infected cells and hence their immunogenicity.
Subscribe to our email newsletter
The composition may be used alone or as an adjuvant with a pox antigen-based vaccine, especially in the treatment or prophylaxis of viral infections such as smallpox.
TapImmune said the transporters associated with antigen presentation (TAP) technology can improve the efficacy of many current prophylactic vaccines and enhance the creation of new ones in the fight against many pandemic infectious diseases.
TapImmune chairman and CEO Glynn Wilson said USPTO has added another important piece to their intellectual property portfolio.
"It provides protection for the development of new products in the prophylactic and biodefense vaccine markets," Wilson said.